Comparative in vivo evaluation of 2 ?Lansoprazole 30 mg Capsule formulations.

Not Applicable

• Conditions: Eosinophilic esophagitis.; Eosinophilic esophagitis; K20.0

• Registration Number: IRCT20180620040164N66
• Lead Sponsor: Dorsa Pharmaceutical Co.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Healthy subjects (male) between 18 – 45 years of age and Body Mass Index (BMI) between 18.5 and 30 (inclusive), calculated as kg/m2.
Subjects with no significant diseases or clinically significant abnormal findings during screening, medical history, clinical examination and laboratory evaluations.
Subjects with normal vital signs.
Subjects who agree with patient consent form.

Exclusion Criteria

History of known sensitivity to the tested product
History of specific disease or unusual values ??in laboratory tests and general clinical examination
Hypertension (blood pressure in a standing position and after at least 5 minutes of rest, systole greater than or equal to 140 mmHg and diastole greater than or equal to 90 mmHg)
Smoking more than 10 cigarettes a day
Loss of more than 500 ml of blood in less than 7 days.

Study & Design

• Study Type: interventional
• Study Design: Not specified